VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
Ascentage Pharma-B (06855.HK) Showcases Six Clinical Studies at ASCO 2026 Highlighting Olverembatinib, Lisaftoclax, and Alrizomadlin
Ascentage Pharma-B (06855.HK) Showcases Six Clinical Studies at ASCO 2026 Highlighting Olverembatinib, Lisaftoclax, and Alrizomadlin
May 22, 2026 07:46 CST Updated 08:03
Share:
